Literature DB >> 30593779

Pipeline for the generation of gene knockout mice using dual sgRNA CRISPR/Cas9-mediated gene editing.

Bita Ghassemi1, Mehdi Shamsara2, Masoud Soleimani3, Jafar Kiani4, Minoo Rassoulzadegan5.   

Abstract

Animal models possess undeniable utility for progress on biomedical research projects and developmental and disease studies. Transgenic mouse models recreating specific disease phenotypes associated with β-hemoglobinopathies have been developed previously. However, traditional methods for gene targeting in mouse using embryonic stem cells (ESCs) are laborious and time consuming. Recently, CRISPR has been developed to facilitate and improve genomic modifications in mouse or isogenic cell lines. Applying CRISPR to gene modification eliminates the time consuming steps of traditional approach including selection of targeted ESC clones and production of chimeric mouse. This study shows that microinjection of a plasmid DNA encoding Cas9 protein along with dual sgRNAs specific to Hbb-bs gene (hemoglobin, beta adult s chain) enables breaking target sequences at exons 2 and 3 positions. The injections led to a knockout allele with efficiency around 10% for deletion of exons 2 and 3 and 20% for indel mutation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; CRISPR/Cas9; Disease model; Gene knockout mouse; β-Thalassemia

Year:  2018        PMID: 30593779     DOI: 10.1016/j.ab.2018.12.002

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  3 in total

1.  Improved efficiency of genome editing by constitutive expression of Cas9 endonuclease in genetically-modified mice.

Authors:  Bita Ghassemi; Monire Jamalkhah; Gelareh Shokri; Mousa Kehtari; Masoud Soleimani; Mehdi Shamsara; Jafar Kiani
Journal:  3 Biotech       Date:  2021-01-11       Impact factor: 2.406

Review 2.  Applications and developments of gene therapy drug delivery systems for genetic diseases.

Authors:  Xiuhua Pan; Hanitrarimalala Veroniaina; Nan Su; Kang Sha; Fenglin Jiang; Zhenghong Wu; Xiaole Qi
Journal:  Asian J Pharm Sci       Date:  2021-06-27       Impact factor: 6.598

Review 3.  The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer.

Authors:  Wei Lv; Tao Li; Shanshan Wang; Huihui Wang; Xuemei Li; Shubing Zhang; Lianzi Wang; Yuanhong Xu; Wei Wei
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.